2024年全球新药研发趋势-82页

免费

3.0 九派 2024-04-03 91 16 5.54MB 80 页免费

侵权投诉

FEBRUARY

2024

Global Trends

in R&D 2024

ACTIVITY, PRODUCTIVITY, AND ENABLERS

Biomedical advances are transforming healthcare globally. The multi-stakeholder

ecosystem that enables this progress has been bueted by the global COVID-19

pandemic and is resetting and refocusing on future opportunities to advance

the understanding of human biology and disease, discover and develop new

therapeutics, and provide evidence of the clinical value of these innovations — for

individual patients, populations, and health systems. By all of the traditional metrics,

including funding levels, numbers of trial starts, drug launches, R&D success rates,

and many others, it is clear that industry and investors continue to see tremendous

value in the vast array of ongoing research programs around the world.

This report assesses the trends in new drug launches

and the overall number of initiated clinical trials. It also

proles the state of R&D funding and the activity of

companies of dierent types. The results of research are

compared to the input eort in a Clinical Development

Productivity Index. The notable acceleration and

adaptability of the innovation ecosystem is examined in

terms of several enablers of R&D productivity, including

the relationship between shortening trial durations

and the ‘white space’ within clinical development

timelines that have been reducing for some diseases and

increasing for others.

The research included in this report was undertaken

independently by the IQVIA Institute for Human

Data Science as a public service, without industry or

government funding. The analytics in this report are

based on proprietary IQVIA databases and/or third-

party information and are not derived from proprietary

sponsor trial information.

The contributions to this report from Mohit Agarwal,

Taskin Ahmed, Chris Bamford, Vaibhav Bhalotia, Tanya

Bhardwaj, Lucy Haggerty, Julia Kern, Bhagyashree

Nawar, Urvashi Porwal, Tanushree Thakur, and dozens of

others at IQVIA are gratefully acknowledged.

Find Out More

If you wish to receive future reports from the IQVIA

Institute for Human Data Science or join our mailing list,

visit iqviainstitute.org.

MURRAY AITKEN

Executive Director

IQVIA Institute for Human Data Science

Introduction

Global Trends in R&D 2024: Activity, Productivity, and Enablers

transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without

express written consent of IQVIA and the IQVIA Institute.

REFERENCING THIS REPORT

Please use this format when referencing content from this report:

Source: IQVIA Institute for Human Data Science. Global Trends in R&D 2024: Activity, Productivity, and Enablers. February 2024.

Available from www.iqviainstitute.org

Table of Contents

Overview 2

R&D funding 4

Clinical trial activity 12

New drug approvals and launches 29

Clinical development productivity 40

Productivity enablers 58

Notes on sources 73

Methodologies 74

References 75

About the authors 76

About the Institute 78

研报加载中……请稍候！
如果长时间未打开，您也可以点击刷新试试。

下载研报到电脑，查找使用更方便

免费 16人已下载

立即下载

摘要：

FEBRUARY2024GlobalTrendsinR&D2024ACTIVITY,PRODUCTIVITY,ANDENABLERSBiomedicaladvancesaretransforminghealthcareglobally.Themulti-stakeholderecosystemthatenablesthisprogresshasbeenbuetedbytheglobalCOVID-19pandemicandisresettingandrefocusingonfutureopportunitiestoadvancetheunderstandingofhumanbiologyan...

展开>> 收起<<

2024年全球新药研发趋势-82页.pdf

共80页,预览10页

还剩页未读，继续阅读